Alnylam Pharmaceuticals (ALNY) Competitors

Royalty Pharma (NASDAQ:RPRX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap finance companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, community ranking, media sentiment and profitability.

Do analysts prefer RPRX or ALNY?

Royalty Pharma currently has a consensus target price of $46.75, indicating a potential upside of 70.56%. Alnylam Pharmaceuticals has a consensus target price of $216.19, indicating a potential upside of 45.65%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Royalty Pharma is more favorable than Alnylam Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Alnylam Pharmaceuticals	0 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.59

Does the media prefer RPRX or ALNY?

In the previous week, Royalty Pharma and Royalty Pharma both had 9 articles in the media. Alnylam Pharmaceuticals' average media sentiment score of 1.17 beat Royalty Pharma's score of 0.74 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger earnings and valuation, RPRX or ALNY?

Royalty Pharma has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.36B	6.95	$1.13B	$1.34	20.46
Alnylam Pharmaceuticals	$1.83B	10.27	-$440.24M	-$2.68	-55.38

Which has more risk & volatility, RPRX or ALNY?

Royalty Pharma has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

Is RPRX or ALNY more profitable?

Royalty Pharma has a net margin of 35.70% compared to Royalty Pharma's net margin of -16.58%. Alnylam Pharmaceuticals' return on equity of 22.94% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	35.70%	22.94%	13.78%
Alnylam Pharmaceuticals	-16.58%	N/A	-8.92%

Do insiders & institutionals believe in RPRX or ALNY?

54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 18.9% of Royalty Pharma shares are owned by company insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Does the MarketBeat Community favor RPRX or ALNY?

Alnylam Pharmaceuticals received 774 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 67.96% of users gave Royalty Pharma an outperform vote.

Company	Underperform	Outperform
Royalty Pharma	Outperform Votes 316 67.96%	Underperform Votes 149 32.04%
Alnylam Pharmaceuticals	Outperform Votes 1090 76.17%	Underperform Votes 341 23.83%

Summary

Royalty Pharma beats Alnylam Pharmaceuticals on 12 of the 17 factors compared between the two stocks.